Rise and shine, everyone, the middle of the week is already here. Congratulations on making it this far and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required. Meanwhile, here is the latest menu of tidbits to help you on your way. Have a wonderful day and please do stay in touch …
The back-to-back deals Sanofi (SNY) is pursuing are giving pause to Moody’s Investor Service. “While Sanofi’s ratings and outlook remain unchanged following the (latest) acquisition, the company’s financial metrics will deteriorate and we caution that Sanofi’s financial flexibility within the (debt) rating category has substantially diminished,” Moody’s wrote in a report. Further debt-financed deals could prove negative for its credit rating or outlook. Sanofi this month agreed to pay $11.6 billion for Bioverativ (BIVV) and $4.8 billion for Ablynx (ABLYF) to boost its blood disorder portfolio.
About the Author Reprints
